Menu
![logo](https://glenmarkpharma-us.com/wp-content/themes/glenmark_us/assets/images/PDF_Banner.png)
News Feed
Glenmark Pharmaceuticals Presenting New Data from Respiratory Portfolio at the ACAAI Annual Scientific Meeting 2017
Mahwah, NJ; October 23, 2017 – Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the company is presenting new data at the upcoming American College of Allergy, Asthma and Immunology Annual Scientific Meeting (ACAAI 2017) in Boston, Massachusetts. The Glenmark presentations include results of clinical trials for GSP 301, an investigational fixed-dose combination treatment for seasonal allergic rhinitis (SAR) and one of the company’s leading pipeline candidates. “Glenmark is growing into a diversified pharmaceutical company with a pipeline of investigational new drugs, and the data being presented at ACAAI 2017 is an important step in that growth,” said Fred Grossman, President and Chief Medical Officer at Glenmark Pharmaceuticals. “These data will form the basis of a New Drug Application, and if approved, GSP 301 will provide another important combination therapy option for the treatment of SAR.” The scheduled times (noted in Eastern Time) of the presentations at the Hynes Convention Center are as follows:
- Efficacy and Safety of Once-daily and Twice-daily Olopatadine/Mometasone Nasal Spray Treatment in Seasonal Allergic Rhinitis
- Presenter: Charles P. Andrews
- Poster #: P433
- Friday, October 27 4:40 PM ET
- Efficacy and Safety of Olopatadine/Mometasone Combination Nasal Spray for the Treatment of Seasonal Allergic Rhinitis
- Presenter: Sudeesh K. Tantry
- Poster #: P434
- Friday, October 27 4:50 PM ET
- Olopatadine/Mometasone Combination Nasal Spray Improves Seasonal Allergic Rhinitis Symptoms in a Ragweed Environmental Exposure Chamber
- Presenter: Ann Marie Salapatek
- Poster #: P435
- Friday, October 27 5:00 PM ET